{"schema_version":"secwatch.filing_event.v1","accession":"0000885725-25-000046","form_type":"8-K","ticker":"BSX","cik":"0000885725","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2025-10-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.484865+00:00","generated_at":"2026-05-17T02:54:56.376851+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Boston Scientific Q3 sales $5.065B (+20.3% reported) beat guidance; adjusted EPS $0.75 beats $0.70-0.72","bullets":["GAAP net income $755M ($0.51 EPS) vs $469M ($0.32) a year ago; adjusted EPS $0.75 vs $0.63.","Cardiovascular sales $3.343B (+22.4% reported); MedSurg $1.722B (+16.4%).","U.S. sales +27.0% reported; EMEA +2.6% reported but -2.0% operational due to ACURATE discontinuation.","FY2025 guidance: reported sales growth ~20%, organic ~15.5%; GAAP EPS $1.97-2.01, adjusted EPS $3.02-3.04.","Agreed to acquire Nalu Medical (neuromodulation) and acquired Elutia's antibiotic-eluting Envelope products."],"urls":{"canonical":"https://secwatch.observer/filing/0000885725-25-000046","json":"https://secwatch.observer/filing/0000885725-25-000046.json","markdown":"https://secwatch.observer/filing/0000885725-25-000046.md","text":"https://secwatch.observer/filing/0000885725-25-000046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/885725/000088572525000046/0000885725-25-000046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/885725/000088572525000046/bsx-20251022.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:54:56.376851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}